Determination of Regulatory Review Period for EMRELIS Patent Extension

Content

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EMRELIS and is publishing
this notice of that determination as required by law. FDA has made the determination because of the submission of applications
to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which
claims that human biological product.

DATES:

Anyone with knowledge that any of the dates as published (see
SUPPLEMENTARY INFORMATION
) are incorrect must submit either electronic or written comments and ask for a redetermination by June 2, 2026. Furthermore,
any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence
during the regulatory review period by September 30, 2026. See “Petitions” in the
SUPPLEMENTARY INFORMATION
section for more information.

ADDRESSES:

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of June 2, 2026. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before
that date.

Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring
that your comment does not include any confidential information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing
process. Please note that if you include your name, contact information, or other information that identifies you in the body
of your comments, that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

• Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments,
except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA-2025-E-3073; and FDA-2025-E-3074 for “Determination of Regulatory
Review Period for Purposes of Patent Extension; EMRELIS.” Received comments, those filed in a timely manner (see
ADDRESSES
), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available,
submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The
Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second
copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and
posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly
available, you can provide this information on the cover sheet and not in the body of your comments and you must identify
this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with
§ 10.20 (21 CFR 10.20) and other applicable disclosure law. For more information about FDA's posting of comments to public
dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts
and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT:

Patrick Clouser, Office of the Commissioner, Food and Drug Administration, 12420 Parklawn Drive, Rockville, MD 20852, 240-402-5276.

SUPPLEMENTARY INFORMATION:

I. Background

The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug and Patent
Term Restoration Act (Pub. L. 100-670) generally provide that a patent may be extended for a period of up to 5 years so long
as the patented item (human drug or biologic product, animal drug product, medical device, food additive, or color additive)
was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period
forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: a testing phase and an approval phase. For human biological products,
the testing phase begins when the exemption to permit the clinical investigations of the biological product becomes effective
and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market
the human biological product and continues until FDA grants permission to market the biological product. Although only a portion
of a regulatory review period may count toward the actual amount of extension that the Director of USPTO may award (for example,
half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's
determination of the length of a regulatory review period for a human biological product will include all of the testing phase
and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA has approved for marketing the human biologic product EMRELIS (telisotuzumab vedotin). EMRELIS is indicated for the treatment
of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein
overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a
prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration
of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical
benefit in a confirmatory trial(s). Subsequent to this approval, the USPTO received patent term restoration applications for
EMRELIS (U.S. Patent Nos. 10,383,948; 10,603,389) from AbbVie Manufacturing Management Unlimited Company.

AbbVie Manufacturing Management Unlimited Company and the USPTO requested FDA's assistance in determining these patents' eligibility
for patent term restoration. In a letter dated October 15, 2025, FDA advised the USPTO that this human biological product
had undergone a regulatory review period and that the approval of EMRELIS represented the first permitted commercial marketing
or use of the product. Thereafter, the USPTO requested that FDA determine the product's regulatory review period.

II. Determination of Regulatory Review Period

FDA has determined that the applicable regulatory review period for EMRELIS is 5,027 days. Of this time, 4,797 days occurred
during the testing phase of the regulatory review period, while 230 days occurred during the approval phase. These periods
of time were derived from the following dates:

1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: August 11, 2011. AbbVie Manufacturing Management Unlimited Company claims that April 24, 2014, is the date the investigational
   new drug application (IND) became effective. However, FDA records indicate that the IND effective date was August 11, 2011,
   which was the first date after receipt of the IND that the investigational studies were allowed to proceed of an earlier IND.

2. The date the application was initially submitted with respect to the human biological product under section 351 of the Public
   Health Service Act (42 U.S.C. 262): September 27, 2024. FDA has verified the applicant's claim that the biologics license application (BLA) for EMRELIS (BLA 761384)
   was initially submitted on September 27, 2024.

3. The date the application was approved: May 14, 2025. FDA has verified the applicant's claim that BLA 761384 was approved on May 14, 2025.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However,
the USPTO applies several statutory limitations in its calculations of the actual period for patent extension. In its application
for patent extension, this applicant seeks 727 days of patent term extension.

III. Petitions

Anyone with knowledge that any of the dates as published are incorrect may submit either electronic or written comments and,
under 21 CFR 60.24, ask

  for a redetermination (see 
  DATES
  ). Furthermore, as specified in § 60.30 (21 CFR 60.30), any interested person may petition FDA for a determination regarding
  whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the
  petition must comply with all the requirements of § 60.30, including but not limited to: must be timely (see 
  DATES
  ), must be filed in accordance with § 10.20, must contain sufficient facts to merit an FDA investigation, and must certify
  that a true and complete copy of the petition has been served upon the patent applicant. (See H. Rept. 857, part 1, 98th Cong.,
  2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Submit petitions electronically to https://www.regulations.gov at Docket No. FDA-2013-S-0610. Submit written petitions (two copies are required) to the Dockets Management Staff (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs. [FR Doc. 2026-06480 Filed 4-2-26; 8:45 am] BILLING CODE 4164-01-P

Download File

Download